Sanofi's $2.2 Billion Acquisition of Inhibrx for Rare-Disease Drug
French healthcare company Sanofi has agreed to acquire U.S. biotech firm Inhibrx for up to $2.2 billion, gaining access to the experimental drug INBRX-101 designed to treat Alpha-1 Antitrypsin Deficiency. The deal includes spinning off Inhibrx's other experimental drugs into a separate company, with Sanofi retaining an 8% stake, and Inhibrx shareholders receiving $30 per share in cash plus shares in the spun-off company. This acquisition aligns with Sanofi's strategy to focus on differentiated and potential best-in-class products, reinforcing its rare disease portfolio.
